NASDAQ · SBFMW
Healthcare · Drug Manufacturers - Specialty & Generic
$0.04
Up+$0.01 (+22.57%)
Updated Aug 16, 2026, 10:20 PM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 10 trading sessions · Daily adjusted prices
SBFMW closed at $0.04 after 10 trading sessions, up 37.50% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $0.0429 | $0.0429 | $0.0429 | $0.0429 | 1K |
| Aug 4, 2026 | $0.0524 | $0.0524 | $0.035 | $0.035 | 790 |
| Aug 3, 2026 | $0.031 | $0.031 | $0.031 | $0.031 | 109 |
| Jul 31, 2026 | $0.031 | $0.031 | $0.031 | $0.031 | 173 |
| Jul 30, 2026 | $0.0548 | $0.0548 | $0.04 | $0.043 | 1.32K |
| Jul 28, 2026 | $0.08 | $0.08 | $0.0318 | $0.0554 | 980 |
| Jul 27, 2026 | $0.08 | $0.08 | $0.08 | $0.08 | 147 |
| Jul 23, 2026 | $0.0321 | $0.0611 | $0.016 | $0.0611 | 25.86K |
| Jul 22, 2026 | $0.0321 | $0.0322 | $0.0321 | $0.0322 | 5.16K |
| Jul 20, 2026 | $0.0312 | $0.0312 | $0.0312 | $0.0312 | 200 |
The latest Smart Investors Daily articles mentioning SBFMW.
SBFMW research
Company profile and research snapshot.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · Jun 25, 2026
FORT LAUDERDALE, FL / ACCESS Newswire / June 25, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of ...
GlobeNewswire Inc. · Apr 28, 2022
MONTREAL, April 28, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today closed its previously announced private placement pursuant to a securities purchase agreement entered into on April 25, 2022 with certain institutional and accredited investors for aggregate gross proceeds of approximately $19.5 million, before deducting fees to the placement agent and other offering expenses payable by the Company.
GlobeNewswire Inc. · Apr 26, 2022
MONTREAL, April 26, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it entered into a securities purchase agreement with certain institutional and accredited investors for aggregate gross proceeds of approximately $19.5 million, before deducting fees to the placement agent and other offering expenses payable by the Company.
GlobeNewswire Inc. · Mar 14, 2022
MONTREAL, March 14, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today closed its previously announced private placement pursuant to a securities purchase agreement entered into on March 10, 2022 with certain institutional and accredited investors.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SBFMW.
No results
No recent SID articles mention SBFMW.
